TY - JOUR AU - Elsaadi, Samah AU - Steiro, Ida AU - Abdollahi, Pegah AU - Vandsemb, Esten N. AU - Yang, Rui AU - Slørdahl, Tobias S. AU - Rø, Torstein Baade AU - Menu, Eline AU - Sponaas, Anne-Marit AU - Børset, Magne PY - 2021 DA - 2021/01/04 TI - Targeting phosphoglycerate dehydrogenase in multiple myeloma JO - Experimental Hematology & Oncology SP - 3 VL - 10 IS - 1 AB - Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of plasma cells in the bone marrow. To date, this disease is still incurable and novel therapeutic approaches are required. Phosphoglycerate dehydrogenase (PHGDH) is the first and rate-limiting enzyme in the de novo serine synthesis pathway, and it has been attributed to bortezomib-resistance in MM. SN - 2162-3619 UR - https://doi.org/10.1186/s40164-020-00196-w DO - 10.1186/s40164-020-00196-w ID - Elsaadi2021 ER -